Herein, we demonstrated that higher RUNX1 expression significantly predicted poor prognosis in MDS patients through multiple layers of analysis, thereby paving the way for targeting RUNX1 in the treatment of MDS patients with higher RUNX1 expression. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.